Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus DECADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus DECADERM.
CAPEX vs DECADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Dexamethasone acts as a glucocorticoid receptor agonist, binding to the cytoplasmic glucocorticoid receptor, leading to modulation of gene transcription, suppression of pro-inflammatory cytokines, and induction of anti-inflammatory proteins, thereby reducing inflammation and immune responses.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
DECADERM (dexamethasone) is typically administered as 0.75-9 mg/day orally in divided doses every 6-12 hours, depending on the condition. For acute indications, higher doses (up to 40 mg/day) may be given intravenously or intramuscularly.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life approximately 36–54 hours (mean 44 h); prolonged in hepatic impairment.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal (primarily as inactive metabolites, <5% unchanged), fecal/biliary (<2%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid